Blog
RSS FeedPosted by Michael Wonder on 07 Apr 2018
Besponsa approved by Health Canada for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
6 April 2018 - First and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory CD22-positive ...
Posted by Michael Wonder on 23 Mar 2018
Health Canada approves Rituxan subcutaneous formulation for Canadians with chronic lymphocytic leukaemia
22 March 2018 - Rituxan SC is a new treatment option for Canadians living with one of the most common forms ...
Posted by Michael Wonder on 21 Mar 2018
BMS withdraws submission for Opdivo for urothelial carcinoma
20 March 2018 - Health Canada's handling of the submission is perplexing. ...
Posted by Michael Wonder on 07 Mar 2018
Health Canada approves Lonsurf (trifluridine/tipiracil) for metastatic colorectal cancer
6 March 2018 - Lonsurf, a new important treatment option for adult patients with metastatic colorectal cancer that has been shown ...
Posted by Michael Wonder on 23 Feb 2018
Health Canada approves Bavencio (avelumab for injection) for the treatment of metastatic Merkel cell carcinoma in previously treated adult patients
22 February 2018 - First Health Canada approved treatment for rare and aggressive type of skin cancer. ...
Posted by Michael Wonder on 16 Feb 2018
Health Canada approves new indication for Zytiga (abiraterone acetate), broadening its use for treatment of newly diagnosed metastatic prostate cancer
15 February 2018 - Zytiga, used in combination with prednisone and androgen deprivation therapy, was shown to reduce the risk ...
Posted by Michael Wonder on 14 Feb 2018
Health Canada approves Ipsen's Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours
13 February 2018 - Somatuline Autogel is the first and only somatostatin analog approved in Canada to treat enteropancreatic neuroendocrine ...
Posted by Michael Wonder on 04 Feb 2018
Tagrisso (osimertinib) receives full Health Canada approval for targeted treatment of non-small-cell lung cancer
31 January 2018 - Approval based on Phase III AURA3 trial that demonstrated significant improvement in progression-free survival with Tagrisso compared ...
Posted by Michael Wonder on 24 Jan 2018
Lartruvo (olaratumab) approved in Canada for the treatment of advanced soft tissue sarcoma in adults
24 January 2018 - Health Canada has issued a Notice of Compliance with Conditions for Lartruvo (olaratumab). ...
Posted by Michael Wonder on 05 Dec 2017
Health Canada approves Rydapt (midostaurin), first targeted therapy for common form of acute myeloid leukaemia
5 December 2017 - Targeted therapy treats most common gene mutation (FLT3) found in more than one third of AML patients. ...
Posted by Michael Wonder on 14 Nov 2017
Xalkori approved by Health Canada for the treatment of patients with ROS1-positive locally advanced or metastatic non-small-cell lung cancer
14 November 2017 - First Health Canada approved treatment for Canadians with ROS1 non-small-cell lung cancer. ...
Posted by Michael Wonder on 07 Nov 2017
Health Canada approves Imfinzi (durvalumab) for previously treated patients with advanced bladder cancer
6 November 2017 - Approval granted based on promising tumour response rate and duration of response. ...
Posted by Michael Wonder on 31 Oct 2017
Janssen announces Imbruvica (ibrutinib) as the first approved treatment for chronic graft-versus-host disease granted by Health Canada priority review
30 October 2017 - Approval provides a much-needed option for patients who develop this life-threatening condition following stem cell transplant. ...
Posted by Michael Wonder on 20 Aug 2017
Gilead receives approval in Canada for Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for re-treatment of certain patients with chronic hepatitis C virus infection
17 August 2017 - VOSEVI is the first once daily, single tablet hepatitis C virus (HCV) regimen for re-treatment, and ...
Posted by Michael Wonder on 14 Aug 2017
Onivyde (irinotecan liposome for injection) has received approval in Canada for the treatment of metastatic adenocarcinoma of the pancreas in the post-gemcitabine setting
11 August 2017 - Onivyde, in combination with 5-fluorouracil and leucovorin, is the first and only treatment shown to increase ...